Vitrolife signs collaboration agreement with Cellartis

Vitrolife signs collaboration agreement with Cellartis

Vitrolife has signed a collaboration agreement with Cellartis AB, Göteborg,
regarding the development of new products for cultivation, handling and
differentiation of stem cells. The new agreement extends the present
collaboration between the companies. The agreement is spanning over 2 years. Its
financial details will not be made public. 


Kungsbacka June 7, 2007

Magnus Nilsson
CEO


Information Cellartis:
Cellartis AB is focused on research, development and production of human
embryonic stem cells and differential cells derived for stem cells. For more
information www.cellartis.com



Queries should be addressed to: 
Magnus Nilsson, CEO, phone +46 31 721 80 00 or +46 708 22 80 61.
Anna Ahlberg, CFO, phone +46 31 721 80 13 or +46 708 22 80 13.

Vitrolife is a global biotechnology/medical device Group that works with
developing, manufacturing and selling advanced products and systems for the
preparation, cultivation and storage of human cells, tissue and organs.  The
company has business activities within three product areas: Fertility,
Transplantation and Stem Cell Cultivation. The Fertility product area works with
nutrient solutions (media) and advanced one-time instruments such as needles and
pipettes, for the treatment of human infertility. The Transplantation product
area works with solutions and systems to maintain tissue in optimal condition
outside the body for the required time while waiting for transplantation. The
Stem Cell Cultivation product area works with media and instruments to enable
the use and handling of stem cells for therapeutic purposes. 
     Vitrolife today has approximately 120 employees and the company's products
are sold in more than 80 markets. The head office is in Kungsbacka, Sweden, and
there are subsidiaries outside Gothenburg, Sweden and in Denver, USA. The
Vitrolife share is listed on the OMX Nordic Exchange's Nordic Small Cap list.